Topic
Anthrax vaccines
About: Anthrax vaccines is a research topic. Over the lifetime, 685 publications have been published within this topic receiving 21495 citations.
Papers published on a yearly basis
Papers
More filters
2 citations
TL;DR: Dendriplexes show superior immunogenicity to naked PA DNA in both mouse strains and that C18 dendriPlexes with 50 �g plasmid DNA are most efficacious, however, the elicited antibodies did not neutralise lethal toxin in vitro, therefore further work is required to improve these preparations in order to elicit functional antibodies.
Abstract: Protective antigen (PA), the binding subunit of toxins produced by Bacillus anthracis is singularly the most important antigen required for specific immunity to anthrax disease. We used cationic poly-lysine dendrons to develop a genetic anthrax vaccine. Plasmid CMV/ER PA83 which encoded full length PA 83 was complexed with dendrons to form dendriplexes. Two types of dendron were used: C0 and C18.These were mixed with DNA to form dendriplexes, of ap- proximately 80 nm in size, which were tested for immunogenicity. A/J and BALB/c mice were vaccinated with dendri- plexes containing 1� g and 50 � g plasmid DNA per dose over a period of 6 weeks. Immunisation with naked PA DNA did not induce an antibody response even after secondary boosting, whereas both dendriplexes produced strong anti-PA anti- body response. This response was dose dependent. We conclude that dendriplexes show superior immunogenicity com- pared to naked PA DNA in both mouse strains and that C18 dendriplexes with 50 �g plasmid DNA are most efficacious. However, the elicited antibodies did not neutralise lethal toxin in vitro. Therefore further work is required to improve these preparations in order to elicit functional antibodies.
1 citations
Patent•
10 Mar 2002
TL;DR: The strain B. anthracis retaining properties in storage and culturing on nutrient media that can be used as producer of different anthrax antigens (antigens of cellular wall, protective antigen, edematous and lethal factors, proteins of S-layer and others) as discussed by the authors.
Abstract: biotechnology. SUBSTANCE: invention proposes the strain B. anthracis retaining properties in storage and culturing on nutrient media that can be used as producer of different anthrax antigens (antigens of cellular wall, protective antigen, edematous and lethal factors, proteins of S-layer and others). Invention can be used in microbiology, genetics, biochemistry, in production of Bacillus anthracis antigens and other biologically active substances that are components of chemical anthrax vaccines and diagnostic preparations. EFFECT: strain indicated above, valuable properties.
1 citations
Patent•
20 Dec 1998
TL;DR: In this paper, anthrax strain cultures are tested preliminary in vitro with respect to their capability to produce toxin in medium of capsule formation and selected cultures at relative content of Tox + KOE 95-98% are subjected for selection on bilayer agar.
Abstract: FIELD: microbiology. SUBSTANCE: anthrax strain cultures are tested preliminary in vitro with respect to their capability to produce toxin in medium of capsule formation. Selected cultures at relative content of Tox + KOE 95-98% are subjected for selection on bilayer agar. Hemolysis zone-forming colonies (size is 2-8 mm) are isolated in 18-24 h. Selected cultures are tested and evaluated with respect to their culture-morpholigical properties, harmless and immunogenicity in vivo. Invention can be used for quality control of living anthrax vaccines. EFFECT: decreased time and cost for vaccine strains, subcultures and ready vaccines testing. 6 tbl, 6 exc
1 citations